Our results are also partially in line with a recent study reporting that high levels of distinct subpopulations of systemic CD8+ and CD4+ T lymphocytes associated with longer breast cancer-specific survival in MBC patients treated with high-dose chemotherapy [27]. This evidence concerns the gene CD8A and breast carcinoma.